



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

10<sup>th</sup> December, 2020

M/s. BSE Ltd.  
Dalal Street, Fort  
Mumbai 400 001

**Scrip Code: 524816**

M/s. National Stock Exchange of India Ltd.  
"Exchange Plaza", Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

**Scrip Code: NATCOPHARM**

Dear Sir,

**Sub:** Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the disclosure of Related Party Transactions for the half year ended September 30, 2020.

This is for your information and records.

Thanking you,

Yours faithfully,  
For NATCO Pharma Limited

A handwritten signature in blue ink, appearing to read "M. Adinarayana".

M. Adinarayana  
Company Secretary &  
Vice President (Legal & Corp. Affairs)

Encl: as above.

**NATCO Pharma Limited**

(All amounts in ₹ millions, except share data and where otherwise stated)

**Related party disclosures, as per Ind AS 24**

**(a) Names of the related parties and nature of relationship (to the extent transactions have taken place during half year ended 30-09-2020)**

Nature of relationship	Names of the related parties
1. Subsidiary company	NATCO Pharma Inc., United States of America Time Cap Overseas Limited, Mauritius NATCO Pharma (Canada) Inc., Canada NATCO Pharma Asia Pte. Ltd., Singapore NATCO Pharma Australia PTY Ltd., Australia NATCO Lifesciences Philippines Inc., Philippines
2. Step-down subsidiary company	Natcofarma Do Brasil Ltda., Brazil
3. Entities in which Directors have control or have significant influence	Time Cap Pharma Labs Limited NATCO Trust
4. Key management personnel ("KMP")	
Chairman and Mangaing Director	Mr. V C Nannapaneni
Vice Chairman and Chief Executive Officer ("CEO")	Mr. Rajeev Nannapaneni
Chief Financial Officer	Mr. S.V.N.N. Appa Rao
Company Secretary	Mr. Adinarayana M
Wholetime Director	Mr. Potluri Prasad Sivaramakrishna
Wholetime Director	Mr. Lingarao Donthineni
5. Non-Executive Directors and Independent Directors	
Independent Director	Mr. Sreerama Murthy Gubbala
Independent Director	Mr. Govinda Prasad Dasu
Independent Director	Mr. Umamaheshwarrao Naidu Madireddi
Independent Director	Mr. Venkateswara Rao Thallapaka
Non-Executive Director	Mr. Sridhar Sankararaman
Independent Director	Mrs. Leela Digumarti
5. Relatives of KMP	Ms. Durga Devi Nannapaneni Dr. N. Ramakrishna Rao V S Swathi Kantamani

**(b) Related party transactions during the year**

**For half year ended  
30 Sep 2020**

<b>Time Cap Overseas Limited, Mauritius</b>	
Investment in equity shares	340.81
Share application money	51.54
Loan repaid *	289.27
Interest received	10.52
Interest income on loan	6.95
<b>NATCO Pharma (Canada) Inc., Canada</b>	
Sale of products	367.51
<b>NATCO Pharma Asia Pte Ltd., Singapore</b>	
Interest income on loan	2.88
Sale of products	22.66
<b>Natcofarma Do Brasil Ltda., Brazil</b>	
Sale of products	35.25
Reimbursement of Expenses	0.90
<b>NATCO Pharma Australia Pty Ltd., Australia</b>	
Investment in equity shares	21.44
<b>NATCO Pharma Inc., United States of America</b>	
Interest income on loan	3.13
<b>Time Cap Pharma Labs Limited</b>	
Rental expense	2.70
<b>NATCO Trust</b>	
Donations (includes contribution to corporate social responsibility activities )	97.98

For NATCO Pharma Limited



S.V.V.N. APPA RAO  
Chief Financial Officer

**NATCO Pharma Limited**

(All amounts in ₹ millions, except share data and where otherwise stated)

(b)

**Related party transactions during the year (continued)**

**For half year ended  
30 Sep 2020**

<b>Mr. V C Nannapaneni</b>	
Short-term employee benefits**	9.25
Rental expense	1.20
<b>Mr. Rajeev Nannapaneni</b>	
Short-term employee benefits**	8.50
Rental expense	1.50
<b>Mr. Potluri Prasad Sivaramakrishna</b>	
Short-term employee benefits**	7.27
ESOP	5.82
<b>Mr. Lingarao Donthineni</b>	
Short-term employee benefits**	7.27
ESOP	5.82
<b>Mr. S.V.N.N. Appa Rao</b>	
Short-term employee benefits**	3.47
ESOP	5.59
<b>Mr. Adinarayana M</b>	
Short-term employee benefits**	2.57
ESOP	5.59
<b>Sitting fees:</b>	
Mr. Govinda Prasad Dasu	0.22
Mrs. Leela Digumarti	0.12
Mr. Umamaheshwarrao Naidu Madireddi	0.28
Mr. Sreerama Murthy Gubbala	0.30
Mr. Venkateswara Rao Thallapaka	0.22

(c)

**Related party closing balances as on balance sheet date receivable/(payable):**

**As at  
30 Sep 2020**

<b>Loan receivable</b>	
NATCO Pharma Inc., United States of America	121.77
NATCO Pharma Asia PTE Ltd., Singapore	112.94
<b>Interest receivable on loans</b>	
NATCO Pharma Inc., United States of America	11.20
Time cap Overseas Limited, Mauritius	6.87
NATCO Pharma Asia PTE Ltd., Singapore	7.18
<b>Trade receivables</b>	
NATCO Pharma (Canada) Inc., Canada	23.42
Natcofarma Do Brasil Ltda., Brazil	299.32
NATCO Pharma Asia PTE Ltd., Singapore	25.64
<b>Trade payable</b>	
Time Cap Pharma Labs Limited	(2.19)
Mr. V.C. Nannapaneni	(0.66)
Mr. Rajeev Nannapaneni	(0.83)
<b>Remuneration payable</b>	
Mr. V.C. Nannapaneni	(0.83)
Mr. Rajeev Nannapaneni	(0.77)
Mr. Lingarao Donthineni	(0.43)
Mr. Potluri Prasad Sivaramakrishna	(0.40)
Mr. S.V.N.N. Appa Rao	(0.55)
Mr. Adinarayana M	(0.21)

\* Loan converted into equity

\*\* This aforesaid amount does not include amounts in respect of gratuity and compensated absences as the same are determined on actuarial basis for the Company as a whole.

For NATCO Pharma Limited



S.V.V.N. APPA RAO  
Chief Financial Officer